7月2日，诺华盘中上涨3.01%，报158.85美元/股，成交额4862.01万美元。
消息面上，诺华宣布其基因替代疗法Itvisma获得欧盟委员会批准，用于治疗2岁及以上脊髓性肌萎缩症（SMA）患者。该疗法为单次给药，通过替代缺陷SMN1基因改善患者运动功能，无需基于体重或年龄调整剂量。审批主要依据III期临床试验数据，患者在52周观察期内运动功能获得统计学显著改善。此前4月该疗法已获欧洲药品管理局CHMP推荐，本次正式获批标志着诺华在罕见病基因治疗领域的商业化进程再进一步。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.